Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

In this activity, experts in oncology discuss current evidence-based guidelines and emerging treatment strategies for small-cell lung cancer (SCLC). For the complete activity, including supporting material, please visit: www.peervoice.com/KBA861. Presented by: Jonathan W. Goldman, MD, and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guideline recommendations for the use of immunotherapy in SCLC; Evaluate the rationale, evidence, and implications of emerging strategies for treatment of extensive-stage (ES)-SCLC, including use of combination therapy in the maintenance phase of first-line treatment; Identify relevant patient and disease-specific considerations that may guide contemporary therapy planning and increase the importance of shared clinical decision-making for ES-SCLC.